The molecular diagnostics firm was told on Wednesday that it is again in compliance with a rule calling for a $1 minimum bid on its share price.
The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.
The company, a division of BGI Group, sold 40.1 million shares at RMB 13.64 per share for a total of RMB 547 million ($80.6 million) in the offering.
The Index gained 2 percent in June, outperforming the Dow and the Nasdaq, but underperforming the Nasdaq Biotechnology Index, which gained nearly 9 percent.
The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.
Analysts have released notes to investors refuting the report's claims, calling the short thesis "flawed," and reiterating their ratings for Exact's stock.
The GenomeWeb Index rose nearly 6 percent in April, vastly outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.
The GW Index outperformed the Dow Jones Industrial Average, the Nasdaq Composite, and the Nasdaq Biotech Index.
The GenomeWeb Index rose nearly 5 percent in February, on par with the Dow and slightly outperforming the Nasdaq.
The GenomeWeb Index rose more than 6 percent in January, outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.
Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.
Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.
Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.
In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.